Cuproptosis key gene FDX1 is a prognostic biomarker and associated with immune infiltration in glioma

Recent studies have found that the protein encoded by the FDX1 gene is involved in mediating Cuproptosis as a regulator of protein lipoylation and related to immune response process of tumors. However, the specific biological function of FDX1 in glioma is currently unclear. To explore the potential...

Full description

Saved in:
Bibliographic Details
Published inFrontiers in medicine Vol. 9; p. 939776
Main Authors Lu, Hanwen, Zhou, Liwei, Zhang, Bingchang, Xie, Yuanyuan, Yang, Huiyin, Wang, Zhanxiang
Format Journal Article
LanguageEnglish
Published Switzerland Frontiers Media S.A 29.11.2022
Subjects
Cuproptosis
glioma
immune infiltration
lipoylation
Medicine
prognostic biomarker
glioma
prognostic biomarker
immune infiltration
Cuproptosis
lipoylation
Online AccessGet full text
ISSN2296-858X
2296-858X
DOI10.3389/fmed.2022.939776

Cover

Abstract Recent studies have found that the protein encoded by the FDX1 gene is involved in mediating Cuproptosis as a regulator of protein lipoylation and related to immune response process of tumors. However, the specific biological function of FDX1 in glioma is currently unclear. To explore the potential function of FDX1 , this study explored the correlation between the expression of FDX1 in cancers and survival prognosis by analyzing the public databases of GEPIA and Cbioportal. Immune infiltration was analyzed by the TIMER2.0 database in tumors. The possible biological processes and functions of FDX1-related in glioma were annotated through gene enrichment. Relationship between Cuproptosis and autophagy was explored through gene co-expression studies. Summary and conclusions of this study: (1) FDX1 is highly expressed in gliomas and associated with poor prognosis in low-grade gliomas (LGG). (2) Gene annotation indicates that FDX1 is mainly involved in the tumor protein lipoylation and cell death. (3) FDX1 expression is positively correlated with the infiltration of immune cells. (4) LIPT2 and NNAT , two other genes involved in lipoylation, may be unidentified marker gene for Cuproptosis. And the Cuproptosis genes related to FDX1 were positively correlated with the expression of autophagy marker genes Atg5 , Atg12 , and BECN-1 . This evidence suggests that there may be some interaction between FDX1 mediated Cuproptosis and autophagy. In summary, FDX1 may serve as a potential immunotherapy target and prognostic marker for Glioma.
AbstractList Recent studies have found that the protein encoded by the FDX1 gene is involved in mediating Cuproptosis as a regulator of protein lipoylation and related to immune response process of tumors. However, the specific biological function of FDX1 in glioma is currently unclear. To explore the potential function of FDX1, this study explored the correlation between the expression of FDX1 in cancers and survival prognosis by analyzing the public databases of GEPIA and Cbioportal. Immune infiltration was analyzed by the TIMER2.0 database in tumors. The possible biological processes and functions of FDX1-related in glioma were annotated through gene enrichment. Relationship between Cuproptosis and autophagy was explored through gene co-expression studies. Summary and conclusions of this study: (1) FDX1 is highly expressed in gliomas and associated with poor prognosis in low-grade gliomas (LGG). (2) Gene annotation indicates that FDX1 is mainly involved in the tumor protein lipoylation and cell death. (3) FDX1 expression is positively correlated with the infiltration of immune cells. (4) LIPT2 and NNAT, two other genes involved in lipoylation, may be unidentified marker gene for Cuproptosis. And the Cuproptosis genes related to FDX1 were positively correlated with the expression of autophagy marker genes Atg5, Atg12, and BECN-1. This evidence suggests that there may be some interaction between FDX1 mediated Cuproptosis and autophagy. In summary, FDX1 may serve as a potential immunotherapy target and prognostic marker for Glioma.Recent studies have found that the protein encoded by the FDX1 gene is involved in mediating Cuproptosis as a regulator of protein lipoylation and related to immune response process of tumors. However, the specific biological function of FDX1 in glioma is currently unclear. To explore the potential function of FDX1, this study explored the correlation between the expression of FDX1 in cancers and survival prognosis by analyzing the public databases of GEPIA and Cbioportal. Immune infiltration was analyzed by the TIMER2.0 database in tumors. The possible biological processes and functions of FDX1-related in glioma were annotated through gene enrichment. Relationship between Cuproptosis and autophagy was explored through gene co-expression studies. Summary and conclusions of this study: (1) FDX1 is highly expressed in gliomas and associated with poor prognosis in low-grade gliomas (LGG). (2) Gene annotation indicates that FDX1 is mainly involved in the tumor protein lipoylation and cell death. (3) FDX1 expression is positively correlated with the infiltration of immune cells. (4) LIPT2 and NNAT, two other genes involved in lipoylation, may be unidentified marker gene for Cuproptosis. And the Cuproptosis genes related to FDX1 were positively correlated with the expression of autophagy marker genes Atg5, Atg12, and BECN-1. This evidence suggests that there may be some interaction between FDX1 mediated Cuproptosis and autophagy. In summary, FDX1 may serve as a potential immunotherapy target and prognostic marker for Glioma.
Recent studies have found that the protein encoded by the FDX1 gene is involved in mediating Cuproptosis as a regulator of protein lipoylation and related to immune response process of tumors. However, the specific biological function of FDX1 in glioma is currently unclear. To explore the potential function of FDX1, this study explored the correlation between the expression of FDX1 in cancers and survival prognosis by analyzing the public databases of GEPIA and Cbioportal. Immune infiltration was analyzed by the TIMER2.0 database in tumors. The possible biological processes and functions of FDX1-related in glioma were annotated through gene enrichment. Relationship between Cuproptosis and autophagy was explored through gene co-expression studies. Summary and conclusions of this study: (1) FDX1 is highly expressed in gliomas and associated with poor prognosis in low-grade gliomas (LGG). (2) Gene annotation indicates that FDX1 is mainly involved in the tumor protein lipoylation and cell death. (3) FDX1 expression is positively correlated with the infiltration of immune cells. (4) LIPT2 and NNAT, two other genes involved in lipoylation, may be unidentified marker gene for Cuproptosis. And the Cuproptosis genes related to FDX1 were positively correlated with the expression of autophagy marker genes Atg5, Atg12, and BECN-1. This evidence suggests that there may be some interaction between FDX1 mediated Cuproptosis and autophagy. In summary, FDX1 may serve as a potential immunotherapy target and prognostic marker for Glioma.
Recent studies have found that the protein encoded by the FDX1 gene is involved in mediating Cuproptosis as a regulator of protein lipoylation and related to immune response process of tumors. However, the specific biological function of FDX1 in glioma is currently unclear. To explore the potential function of FDX1 , this study explored the correlation between the expression of FDX1 in cancers and survival prognosis by analyzing the public databases of GEPIA and Cbioportal. Immune infiltration was analyzed by the TIMER2.0 database in tumors. The possible biological processes and functions of FDX1-related in glioma were annotated through gene enrichment. Relationship between Cuproptosis and autophagy was explored through gene co-expression studies. Summary and conclusions of this study: (1) FDX1 is highly expressed in gliomas and associated with poor prognosis in low-grade gliomas (LGG). (2) Gene annotation indicates that FDX1 is mainly involved in the tumor protein lipoylation and cell death. (3) FDX1 expression is positively correlated with the infiltration of immune cells. (4) LIPT2 and NNAT , two other genes involved in lipoylation, may be unidentified marker gene for Cuproptosis. And the Cuproptosis genes related to FDX1 were positively correlated with the expression of autophagy marker genes Atg5 , Atg12 , and BECN-1 . This evidence suggests that there may be some interaction between FDX1 mediated Cuproptosis and autophagy. In summary, FDX1 may serve as a potential immunotherapy target and prognostic marker for Glioma.
Recent studies have found that the protein encoded by the gene is involved in mediating Cuproptosis as a regulator of protein lipoylation and related to immune response process of tumors. However, the specific biological function of in glioma is currently unclear. To explore the potential function of , this study explored the correlation between the expression of in cancers and survival prognosis by analyzing the public databases of GEPIA and Cbioportal. Immune infiltration was analyzed by the TIMER2.0 database in tumors. The possible biological processes and functions of FDX1-related in glioma were annotated through gene enrichment. Relationship between Cuproptosis and autophagy was explored through gene co-expression studies. Summary and conclusions of this study: (1) FDX1 is highly expressed in gliomas and associated with poor prognosis in low-grade gliomas (LGG). (2) Gene annotation indicates that FDX1 is mainly involved in the tumor protein lipoylation and cell death. (3) expression is positively correlated with the infiltration of immune cells. (4) and , two other genes involved in lipoylation, may be unidentified marker gene for Cuproptosis. And the Cuproptosis genes related to FDX1 were positively correlated with the expression of autophagy marker genes , , and . This evidence suggests that there may be some interaction between FDX1 mediated Cuproptosis and autophagy. In summary, FDX1 may serve as a potential immunotherapy target and prognostic marker for Glioma.
Author Zhang, Bingchang
Wang, Zhanxiang
Yang, Huiyin
Zhou, Liwei
Xie, Yuanyuan
Lu, Hanwen
AuthorAffiliation 2 Institute of Neurosurgery, School of Medicine, Xiamen University , Xiamen , China
3 Department of Neurosurgery, The First Affiliated Hospital of Xiamen University , Xiamen , China
1 Department of Neurosurgery, Xiamen Key Laboratory of Brain Center, The First Affiliated Hospital of Xiamen University , Xiamen , China
AuthorAffiliation_xml – name: 1 Department of Neurosurgery, Xiamen Key Laboratory of Brain Center, The First Affiliated Hospital of Xiamen University , Xiamen , China
– name: 3 Department of Neurosurgery, The First Affiliated Hospital of Xiamen University , Xiamen , China
– name: 2 Institute of Neurosurgery, School of Medicine, Xiamen University , Xiamen , China
Author_xml – sequence: 1
  givenname: Hanwen
  surname: Lu
  fullname: Lu, Hanwen
– sequence: 2
  givenname: Liwei
  surname: Zhou
  fullname: Zhou, Liwei
– sequence: 3
  givenname: Bingchang
  surname: Zhang
  fullname: Zhang, Bingchang
– sequence: 4
  givenname: Yuanyuan
  surname: Xie
  fullname: Xie, Yuanyuan
– sequence: 5
  givenname: Huiyin
  surname: Yang
  fullname: Yang, Huiyin
– sequence: 6
  givenname: Zhanxiang
  surname: Wang
  fullname: Wang, Zhanxiang
BackLink https://www.ncbi.nlm.nih.gov/pubmed/36523779$$D View this record in MEDLINE/PubMed
BookMark eNp1Uk1v3CAQRVWq5vPeU8Wxl93wYYO5VKq2TRopUi-NlBvCeHBIbNiCnSr_vjibRkmknoCZ997MMO8Q7YUYAKGPlKw5b9SpG6FbM8LYWnElpXiHDhhTYtXUzfXei_s-Osn5lhBCOasryj-gfS5qxqVUBwg28zbF7RSzz_gOHnAPAfDZt2uKS8DgkuxDzJO3uPVxNOkOEjahwybnaL2ZoMN__HSD_TjOhemD88OUzORjKA_cDwvrGL13Zshw8nQeoauz7782P1aXP88vNl8vV7YSbFrVTnDX2o6Bs4wSJTjrnHSiqVjTMMq4NcQK54zhUnXCqVZBxUQLpjKUCcuP0MVOt4vmVm-TLw0_6Gi8fgzE1GuTyiwDaCOFAOEsaSpTsY62FpR0LeGcg2xBFK0vO63t3JafthDKWMMr0deZ4G90H--1klXN-SLw-Ukgxd8z5EmPPlsYBhMgzlkzWde1FA2VBfrpZa3nIv_2VABkB7Ap5pzAPUMo0Ysb9OIGvbhB79xQKOINxfrpcS-lWz_8n_gXPie8mQ
CitedBy_id crossref_primary_10_3389_fimmu_2025_1526961
crossref_primary_10_1155_2024_2868534
crossref_primary_10_26599_AGR_2024_9340024
crossref_primary_10_3390_molecules29122852
crossref_primary_10_3390_biomedicines12071546
crossref_primary_10_1002_jcla_24981
crossref_primary_10_1016_j_biopha_2023_116115
crossref_primary_10_1186_s12935_023_03189_x
crossref_primary_10_3389_fonc_2024_1397863
crossref_primary_10_1007_s11596_024_2832_z
Cites_doi 10.3389/fphar.2021.731798
10.1007/s11864-021-00930-4
10.3389/fonc.2022.967159
10.1093/neuonc/noac042
10.1155/2020/6283796
10.3322/canjclin.39.6.399
10.4238/2015.April.17.3
10.1002/ijc.23513
10.1002/cam4.4344
10.1007/s10555-021-09997-9
10.1093/nar/gkq537
10.2174/1386207325666220221100429
10.1016/j.jfma.2022.03.017
10.1186/s13046-019-1409-3
10.1007/s00432-022-04382-7
10.1155/2022/9196540
10.1016/j.cbpa.2017.11.003
10.1126/science.abf0529
10.1021/acs.biochem.6b00447
10.1002/hep.23841
10.1021/acs.analchem.1c04959
10.1093/neuonc/noaa200
10.1158/2326-6066.CIR-20-0586
10.3389/fimmu.2018.02737
10.3390/cells10061438
10.3389/fphar.2021.749134
10.1186/s40164-022-00277-y
10.20517/2394-4722.2021.72
10.3389/fimmu.2021.711433
10.3233/CBM-200939
10.3390/ijms23063238
10.1093/plphys/kiab501
10.3390/cancers14071627
10.3389/fonc.2020.581051
10.3322/caac.21708
10.3389/fgene.2022.788580
10.3892/or.2020.7831
10.3389/fcell.2021.713569
10.2147/OTT.S282763
10.1016/j.jmb.2011.09.010
10.1073/pnas.1004250107
10.1016/j.lungcan.2021.01.007
10.3390/cancers13061188
10.1016/j.cub.2020.06.081
10.3390/cancers14061498
10.1038/s41417-020-0174-y
10.1111/j.1432-1033.1997.00833.x
10.3389/fcell.2019.00060
10.3390/cells10082032
10.1016/j.ctrv.2019.04.003
10.1016/j.ccr.2005.05.024
10.3322/caac.21654
10.3390/ijms22126288
10.1007/s11912-022-01250-y
10.14245/ns.2143210.605
10.3389/fonc.2021.805628
10.1007/978-981-15-3266-5_9
10.1104/pp.112.208181
10.1016/j.esmoop.2021.100325
10.7150/ijbs.44943
10.3389/fonc.2021.812916
10.1002/bit.27526
10.1021/acs.jmedchem.5b00783
10.1016/j.semcancer.2022.03.014
10.1093/bioinformatics/btz210
10.3389/fgene.2022.878658
10.1136/jitc-2021-004412
10.3390/cancers13174255
10.1002/path.5757
10.1016/j.oraloncology.2019.104460
10.1093/nar/gkx1090
10.1016/j.gpb.2020.10.005
10.3389/fgene.2022.923737
10.1001/jamanetworkopen.2022.9553
10.1023/A:1014566604005
10.1007/978-3-319-95294-9_5
10.3389/fmolb.2021.714053
10.3389/fcell.2021.749157
ContentType Journal Article
Copyright Copyright © 2022 Lu, Zhou, Zhang, Xie, Yang and Wang.
Copyright © 2022 Lu, Zhou, Zhang, Xie, Yang and Wang. 2022 Lu, Zhou, Zhang, Xie, Yang and Wang
Copyright_xml – notice: Copyright © 2022 Lu, Zhou, Zhang, Xie, Yang and Wang.
– notice: Copyright © 2022 Lu, Zhou, Zhang, Xie, Yang and Wang. 2022 Lu, Zhou, Zhang, Xie, Yang and Wang
DBID AAYXX
CITATION
NPM
7X8
5PM
DOA
DOI 10.3389/fmed.2022.939776
DatabaseName CrossRef
PubMed
MEDLINE - Academic
PubMed Central (Full Participant titles)
DOAJ Directory of Open Access Journals
DatabaseTitle CrossRef
PubMed
MEDLINE - Academic
DatabaseTitleList MEDLINE - Academic

CrossRef

PubMed
Database_xml – sequence: 1
  dbid: DOA
  name: DOAJ Directory of Open Access Journals
  url: https://www.doaj.org/
  sourceTypes: Open Website
– sequence: 2
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 2296-858X
ExternalDocumentID oai_doaj_org_article_a766e6fc084a42d1bce97fb0333e7be6
PMC9745336
36523779
10_3389_fmed_2022_939776
Genre Journal Article
GrantInformation_xml – fundername: ;
  grantid: 2020J02063; 2020J05294
– fundername: ;
  grantid: 3502Z20209005
– fundername: ;
  grantid: 82072777
GroupedDBID 53G
5VS
9T4
AAFWJ
AAYXX
ACGFS
ACXDI
ADBBV
ADRAZ
AFPKN
ALMA_UNASSIGNED_HOLDINGS
AOIJS
BAWUL
BCNDV
CITATION
DIK
GROUPED_DOAJ
HYE
KQ8
M48
M~E
OK1
PGMZT
RPM
IPNFZ
NPM
RIG
7X8
5PM
ID FETCH-LOGICAL-c462t-5f63fbcd2efc2109632df7f6842882123ca0c6ffaa379d6f9b9e426bea4a126c3
IEDL.DBID M48
ISSN 2296-858X
IngestDate Wed Aug 27 01:20:26 EDT 2025
Thu Aug 21 18:39:27 EDT 2025
Thu Sep 04 23:06:50 EDT 2025
Mon Jul 21 05:32:13 EDT 2025
Thu Apr 24 23:12:43 EDT 2025
Tue Jul 01 04:05:43 EDT 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Keywords glioma
prognostic biomarker
immune infiltration
Cuproptosis
lipoylation
Language English
License Copyright © 2022 Lu, Zhou, Zhang, Xie, Yang and Wang.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c462t-5f63fbcd2efc2109632df7f6842882123ca0c6ffaa379d6f9b9e426bea4a126c3
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
Reviewed by: Xing Niu, China Medical University, China; Xuxu Gou, University of California, San Francisco, United States; Pinuccia Faviana, University of Pisa, Italy
This article was submitted to Gene and Cell Therapy, a section of the journal Frontiers in Medicine
Edited by: Jinhui Liu, Nanjing Medical University, China
These authors share first authorship
OpenAccessLink http://journals.scholarsportal.info/openUrl.xqy?doi=10.3389/fmed.2022.939776
PMID 36523779
PQID 2755576817
PQPubID 23479
ParticipantIDs doaj_primary_oai_doaj_org_article_a766e6fc084a42d1bce97fb0333e7be6
pubmedcentral_primary_oai_pubmedcentral_nih_gov_9745336
proquest_miscellaneous_2755576817
pubmed_primary_36523779
crossref_primary_10_3389_fmed_2022_939776
crossref_citationtrail_10_3389_fmed_2022_939776
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2022-11-29
PublicationDateYYYYMMDD 2022-11-29
PublicationDate_xml – month: 11
  year: 2022
  text: 2022-11-29
  day: 29
PublicationDecade 2020
PublicationPlace Switzerland
PublicationPlace_xml – name: Switzerland
PublicationTitle Frontiers in medicine
PublicationTitleAlternate Front Med (Lausanne)
PublicationYear 2022
Publisher Frontiers Media S.A
Publisher_xml – name: Frontiers Media S.A
References Li (B33) 2020; 16
Siegel (B2) 2022; 72
Conger (B5) 1967; 56
Sheftel (B17) 2010; 107
Wei (B32) 2020; 2020
Karasarides (B50) 2022; 10
Barthel (B10) 2022; 41
Wasilewski (B51) 2022; 5
Anderson (B23) 2020; 30
Li (B62) 2021; 45
Armengaud (B15) 1997; 247
Dantoing (B65) 2021; 22
Rowland (B80) 2018; 42
Liu (B30) 2019; 7
Cramer (B66) 2019; 99
Zhang (B77) 2022; 2022
Gaikwad (B49) 2022
Binder (B14) 2002; 56
Chyuan (B28) 2021; 13
Jain (B73) 2021; 11
Zhang (B75) 2022; 13
Assie (B52) 2022; 14
Ewen (B16) 2011; 413
Liu (B54) 2022; 121
Xu (B41) 2021; 12
Huang (B53) 2022; 23
Bhargav (B9) 2021; 11
Sun (B36) 2022; 25
Li (B46) 2021; 9
Zhang (B81) 2020; 117
Zhao (B21) 2022; 13
Brunner-Weinzierl (B68) 2018; 9
Andersen (B35) 2021; 255
Pouliquen (B13) 2008; 123
Schaafsma (B37) 2021; 7
Gajewski (B31) 2021; 1
Cripps (B56) 2010; 52
Pacini (B82) 2015; 58
Wang (B57) 2015; 14
Denoix (B3) 1955; 62
Najem (B71) 2021; 10
Wang (B78) 2022
Przybyla-Toscano (B79) 2022; 188
Cai (B18) 2017; 56
Vasaikar (B60) 2018; 46
Jia (B7) 2022; 11
Ciardiello (B67) 2019; 76
Warde-Farley (B59) 2010; 38
van Lis (B19) 2013; 161
Wang (B40) 2020; 10
Siegel (B1) 2021; 71
Andersen (B34) 2021; 13
Ru (B61) 2019; 35
Li (B11) 2022; 94
Amemiya (B22) 2021; 153
Liu (B63) 2021; 12
Harrison (B12) 2021; 10
Dubrawsky (B4) 1989; 39
Tsvetkov (B20) 2022; 375
Ghosh (B24) 2018; 1092
Zheng (B45) 2021; 14
Bjorkblom (B8) 2022; 24
Ostrom (B6) 2020; 22
Yan (B42) 2021; 31
Oswald (B38) 2022; 10
Yang (B43) 2022; 13
Zhang (B74) 2021; 12
Zhao (B44) 2021; 9
Mestrallet (B55) 2021; 10
Zhao (B58) 2021; 19
Ye (B76) 2022; 12
Yuan (B72) 2022; 23
Grady (B69) 2022; 19
Yin (B29) 2019; 38
Murthy (B39) 2021; 11
Joyce (B26) 2005; 7
Lechpammer (B70) 2022; 14
Zhang (B48) 2020; 1248
Choucair (B25) 2020; 27
Gong (B47) 2021; 8
Cook (B27) 2022; 24
Nakamura (B64) 2021; 6
37492249 - Front Med (Lausanne). 2023 Jul 10;10:1244638
References_xml – volume: 12
  year: 2021
  ident: B63
  article-title: PD-1/PD-L1 checkpoint inhibitors in tumor immunotherapy.
  publication-title: Front Pharmacol.
  doi: 10.3389/fphar.2021.731798
– volume: 23
  start-page: 188
  year: 2022
  ident: B72
  article-title: Current WHO guidelines and the critical role of genetic parameters in the classification of glioma: opportunities for immunotherapy.
  publication-title: Curr Treat Options Oncol.
  doi: 10.1007/s11864-021-00930-4
– volume: 12
  year: 2022
  ident: B76
  article-title: Development and validation of cuproptosis-associated prognostic signatures in WHO 2/3 glioma.
  publication-title: Front Oncol.
  doi: 10.3389/fonc.2022.967159
– volume: 24
  start-page: 1454
  year: 2022
  ident: B8
  article-title: Distinct metabolic hallmarks of WHO classified adult glioma subtypes.
  publication-title: Neuro Oncol.
  doi: 10.1093/neuonc/noac042
– volume: 2020
  year: 2020
  ident: B32
  article-title: Cellular and extracellular components in tumor microenvironment and their application in early diagnosis of cancers.
  publication-title: Anal Cell Pathol.
  doi: 10.1155/2020/6283796
– volume: 39
  year: 1989
  ident: B4
  article-title: Cancer statistics.
  publication-title: CA Cancer J Clin.
  doi: 10.3322/canjclin.39.6.399
– volume: 14
  start-page: 3545
  year: 2015
  ident: B57
  article-title: Role of TGFB1 polymorphism in the development of metastatic brain tumors in non-small cell lung cancer patients.
  publication-title: Genet Mol Res.
  doi: 10.4238/2015.April.17.3
– volume: 123
  start-page: 288
  year: 2008
  ident: B13
  article-title: Dietary prevention of malignant glioma aggressiveness, implications in oxidant stress and apoptosis.
  publication-title: Int J Cancer.
  doi: 10.1002/ijc.23513
– volume: 56
  year: 1967
  ident: B5
  article-title: Cancer statistics.
  publication-title: J Med Assoc Ga.
– volume: 10
  start-page: 8387
  year: 2021
  ident: B12
  article-title: Aggressiveness of care at end of life in patients with high-grade glioma.
  publication-title: Cancer Med.
  doi: 10.1002/cam4.4344
– volume: 41
  start-page: 53
  year: 2022
  ident: B10
  article-title: Glioma: molecular signature and crossroads with tumor microenvironment.
  publication-title: Cancer Metastasis Rev.
  doi: 10.1007/s10555-021-09997-9
– volume: 38
  start-page: W214
  year: 2010
  ident: B59
  article-title: The GeneMANIA prediction server: biological network integration for gene prioritization and predicting gene function.
  publication-title: Nucleic Acids Res.
  doi: 10.1093/nar/gkq537
– volume: 25
  start-page: 2082
  year: 2022
  ident: B36
  article-title: A study on immune cell infiltration in lung adenocarcinoma.
  publication-title: Comb Chem High Throughput Screen.
  doi: 10.2174/1386207325666220221100429
– volume: 121
  start-page: 1371
  year: 2022
  ident: B54
  article-title: Immune checkpoint inhibitors for hepatocellular carcinoma – a game changer in treatment landscape.
  publication-title: J Formos Med Assoc.
  doi: 10.1016/j.jfma.2022.03.017
– volume: 38
  year: 2019
  ident: B29
  article-title: Targeting T cell metabolism in the tumor microenvironment: an anti-cancer therapeutic strategy.
  publication-title: J Exp Clin Cancer Res.
  doi: 10.1186/s13046-019-1409-3
– year: 2022
  ident: B78
  article-title: High expression of cuproptosis-related gene FDX1 in relation to good prognosis and immune cells infiltration in colon adenocarcinoma (COAD).
  publication-title: J Cancer Res Clin Oncol.
  doi: 10.1007/s00432-022-04382-7
– volume: 2022
  year: 2022
  ident: B77
  article-title: Novel cuprotosis-related Gene FDX1 signature for overall survival prediction in clear cell renal cell carcinoma patients.
  publication-title: Biomed Res Int.
  doi: 10.1155/2022/9196540
– volume: 42
  start-page: 76
  year: 2018
  ident: B80
  article-title: Protein lipoylation: an evolutionarily conserved metabolic regulator of health and disease.
  publication-title: Curr Opin Chem Biol.
  doi: 10.1016/j.cbpa.2017.11.003
– volume: 375
  start-page: 1254
  year: 2022
  ident: B20
  article-title: Copper induces cell death by targeting lipoylated TCA cycle proteins.
  publication-title: Science.
  doi: 10.1126/science.abf0529
– volume: 56
  start-page: 487
  year: 2017
  ident: B18
  article-title: Human Mitochondrial Ferredoxin 1 (FDX1) and Ferredoxin 2 (FDX2) both bind cysteine desulfurase and donate electrons for iron-sulfur cluster biosynthesis.
  publication-title: Biochemistry.
  doi: 10.1021/acs.biochem.6b00447
– volume: 52
  start-page: 1350
  year: 2010
  ident: B56
  article-title: Type 1 T helper cells induce the accumulation of myeloid-derived suppressor cells in the inflamed Tgfb1 knockout mouse liver.
  publication-title: Hepatology.
  doi: 10.1002/hep.23841
– volume: 94
  start-page: 3245
  year: 2022
  ident: B11
  article-title: Selective single-cell expansion on a microfluidic chip for studying heterogeneity of glioma stem cells.
  publication-title: Anal Chem.
  doi: 10.1021/acs.analchem.1c04959
– volume: 22
  start-page: iv1
  year: 2020
  ident: B6
  article-title: CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2013-2017.
  publication-title: Neuro Oncol.
  doi: 10.1093/neuonc/noaa200
– volume: 10
  start-page: 372
  year: 2022
  ident: B50
  article-title: Hallmarks of resistance to immune-checkpoint inhibitors.
  publication-title: Cancer Immunol Res.
  doi: 10.1158/2326-6066.CIR-20-0586
– volume: 9
  year: 2018
  ident: B68
  article-title: CTLA-4 and PD-1 Control of T-Cell motility and migration: implications for tumor immunotherapy.
  publication-title: Front Immunol.
  doi: 10.3389/fimmu.2018.02737
– volume: 10
  year: 2021
  ident: B55
  article-title: Human keratinocytes inhibit CD4(+) T-Cell proliferation through TGFB1 secretion and surface expression of HLA-G1 and PD-L1 immune checkpoints.
  publication-title: Cells.
  doi: 10.3390/cells10061438
– volume: 12
  year: 2021
  ident: B74
  article-title: FDX1 can impact the prognosis and mediate the metabolism of lung adenocarcinoma.
  publication-title: Front Pharmacol.
  doi: 10.3389/fphar.2021.749134
– volume: 11
  year: 2022
  ident: B7
  article-title: Heterogeneity of the tumor immune microenvironment and its clinical relevance.
  publication-title: Exp Hematol Oncol.
  doi: 10.1186/s40164-022-00277-y
– volume: 7
  start-page: 10.20517/2394
  year: 2021
  ident: B37
  article-title: B cell infiltration is highly associated with prognosis and an immune-infiltrated tumor microenvironment in neuroblastoma.
  publication-title: J Cancer Metastasis Treat.
  doi: 10.20517/2394-4722.2021.72
– volume: 12
  year: 2021
  ident: B41
  article-title: Landscape of immune microenvironment under immune cell infiltration pattern in breast cancer.
  publication-title: Front Immunol.
  doi: 10.3389/fimmu.2021.711433
– volume: 31
  start-page: 87
  year: 2021
  ident: B42
  article-title: Molecular mechanisms, immune cell infiltration, and potential drugs for prostate cancer.
  publication-title: Cancer Biomark.
  doi: 10.3233/CBM-200939
– volume: 23
  year: 2022
  ident: B53
  article-title: Targeting DNA damage response and immune checkpoint for anticancer therapy.
  publication-title: Int J Mol Sci.
  doi: 10.3390/ijms23063238
– volume: 188
  start-page: 997
  year: 2022
  ident: B79
  article-title: Protein lipoylation in mitochondria requires Fe-S cluster assembly factors NFU4 and NFU5.
  publication-title: Plant Physiol.
  doi: 10.1093/plphys/kiab501
– volume: 14
  year: 2022
  ident: B70
  article-title: Advances in immunotherapy for the treatment of adult glioblastoma: overcoming chemical and physical barriers.
  publication-title: Cancers.
  doi: 10.3390/cancers14071627
– volume: 10
  year: 2020
  ident: B40
  article-title: Immune cell infiltration of the primary tumor microenvironment predicted the treatment outcome of chemotherapy with or without bevacizumab in metastatic colorectal cancer patients.
  publication-title: Front Oncol.
  doi: 10.3389/fonc.2020.581051
– volume: 72
  start-page: 7
  year: 2022
  ident: B2
  article-title: Cancer statistics, 2022.
  publication-title: CA Cancer J Clin.
  doi: 10.3322/caac.21708
– volume: 13
  year: 2022
  ident: B21
  article-title: Comprehensive analysis of tumor immune microenvironment characteristics for the prognostic prediction and immunotherapy of oral squamous cell carcinoma.
  publication-title: Front Genet.
  doi: 10.3389/fgene.2022.788580
– volume: 45
  start-page: 5
  year: 2021
  ident: B62
  article-title: PDL1/PD1 blockade in breast cancer: The immunotherapy era (Review).
  publication-title: Oncol Rep.
  doi: 10.3892/or.2020.7831
– volume: 11
  start-page: 3674
  year: 2021
  ident: B39
  article-title: Increased apoptosis is associated with robust immune cell infiltration and cytolytic activity in breast cancer.
  publication-title: Am J Cancer Res.
– volume: 9
  year: 2021
  ident: B44
  article-title: Identification of immune cell infiltration landscape and their prognostic significance in uveal melanoma.
  publication-title: Front Cell Dev Biol.
  doi: 10.3389/fcell.2021.713569
– volume: 62
  year: 1955
  ident: B3
  article-title: Cancer, statistics and surgery.
  publication-title: Gaz Med Fr.
– volume: 14
  start-page: 2085
  year: 2021
  ident: B45
  article-title: Global characterization of immune infiltration in clear cell renal cell carcinoma.
  publication-title: Onco Targets Ther.
  doi: 10.2147/OTT.S282763
– volume: 413
  start-page: 940
  year: 2011
  ident: B16
  article-title: Functional characterization of FDX1: evidence for an evolutionary relationship between P450-type and ISC-type ferredoxins.
  publication-title: J Mol Biol.
  doi: 10.1016/j.jmb.2011.09.010
– volume: 107
  start-page: 11775
  year: 2010
  ident: B17
  article-title: Humans possess two mitochondrial ferredoxins, FDX1 and Fdx2, with distinct roles in steroidogenesis, heme, and Fe/S cluster biosynthesis.
  publication-title: Proc Natl Acad Sci U.S.A.
  doi: 10.1073/pnas.1004250107
– volume: 153
  start-page: 56
  year: 2021
  ident: B22
  article-title: Prognostic impact of the tumor immune microenvironment in pulmonary pleomorphic carcinoma.
  publication-title: Lung Cancer.
  doi: 10.1016/j.lungcan.2021.01.007
– volume: 13
  year: 2021
  ident: B28
  article-title: Targeting the tumor microenvironment for improving therapeutic effectiveness in cancer immunotherapy: focusing on immune checkpoint inhibitors and combination therapies.
  publication-title: Cancers.
  doi: 10.3390/cancers13061188
– volume: 30
  start-page: R921
  year: 2020
  ident: B23
  article-title: The tumor microenvironment.
  publication-title: Curr Biol.
  doi: 10.1016/j.cub.2020.06.081
– volume: 14
  year: 2022
  ident: B52
  article-title: Immune-checkpoint inhibitors for malignant pleural mesothelioma: a french, multicenter, retrospective real-world study.
  publication-title: Cancers.
  doi: 10.3390/cancers14061498
– volume: 27
  start-page: 841
  year: 2020
  ident: B25
  article-title: TMB: a promising immune-response biomarker, and potential spearhead in advancing targeted therapy trials.
  publication-title: Cancer Gene Ther.
  doi: 10.1038/s41417-020-0174-y
– volume: 247
  start-page: 833
  year: 1997
  ident: B15
  article-title: Molecular characterization of FDX1, a putidaredoxin-type [2Fe-2S] ferredoxin able to transfer electrons to the dioxin dioxygenase of Sphingomonas sp. RW1.
  publication-title: Eur J Biochem.
  doi: 10.1111/j.1432-1033.1997.00833.x
– volume: 7
  year: 2019
  ident: B30
  article-title: Cancer-associated fibroblasts build and secure the tumor microenvironment.
  publication-title: Front Cell Dev Biol.
  doi: 10.3389/fcell.2019.00060
– volume: 10
  year: 2021
  ident: B71
  article-title: Immune microenvironment landscape in CNS tumors and role in responses to immunotherapy.
  publication-title: Cells.
  doi: 10.3390/cells10082032
– volume: 76
  start-page: 22
  year: 2019
  ident: B67
  article-title: Immunotherapy of colorectal cancer: challenges for therapeutic efficacy.
  publication-title: Cancer Treat Rev.
  doi: 10.1016/j.ctrv.2019.04.003
– volume: 7
  start-page: 513
  year: 2005
  ident: B26
  article-title: Therapeutic targeting of the tumor microenvironment.
  publication-title: Cancer Cell.
  doi: 10.1016/j.ccr.2005.05.024
– volume: 71
  start-page: 7
  year: 2021
  ident: B1
  article-title: Cancer Statistics, 2021.
  publication-title: CA Cancer J Clin.
  doi: 10.3322/caac.21654
– volume: 22
  year: 2021
  ident: B65
  article-title: Anti-PD1/PD-L1 immunotherapy for non-small cell lung cancer with actionable oncogenic driver mutations.
  publication-title: Int J Mol Sci.
  doi: 10.3390/ijms22126288
– volume: 24
  start-page: 1121
  year: 2022
  ident: B27
  article-title: Targeting the tumor microenvironment in lymphomas: emerging biological insights and therapeutic strategies.
  publication-title: Curr Oncol Rep.
  doi: 10.1007/s11912-022-01250-y
– volume: 19
  start-page: 13
  year: 2022
  ident: B69
  article-title: Glioma immunotherapy: advances and challenges for spinal cord gliomas.
  publication-title: Neurospine.
  doi: 10.14245/ns.2143210.605
– volume: 11
  year: 2021
  ident: B9
  article-title: Mechanical properties in the glioma microenvironment: emerging insights and theranostic opportunities.
  publication-title: Front Oncol.
  doi: 10.3389/fonc.2021.805628
– volume: 1248
  start-page: 201
  year: 2020
  ident: B48
  article-title: Functions of immune checkpoint molecules beyond immune evasion.
  publication-title: Adv Exp Med Biol.
  doi: 10.1007/978-981-15-3266-5_9
– volume: 161
  start-page: 57
  year: 2013
  ident: B19
  article-title: Chlamydomonas reinhardtii chloroplasts contain a homodimeric pyruvate:ferredoxin oxidoreductase that functions with FDX1.
  publication-title: Plant Physiol.
  doi: 10.1104/pp.112.208181
– volume: 6
  year: 2021
  ident: B64
  article-title: Anti-PD-1 antibody monotherapy versus anti-PD-1 plus anti-CTLA-4 combination therapy as first-line immunotherapy in unresectable or metastatic mucosal melanoma: a retrospective, multicenter study of 329 Japanese cases (JMAC study).
  publication-title: ESMO Open.
  doi: 10.1016/j.esmoop.2021.100325
– volume: 16
  start-page: 2014
  year: 2020
  ident: B33
  article-title: Mechanical tumor microenvironment and transduction: cytoskeleton mediates cancer cell invasion and metastasis.
  publication-title: Int J Biol Sci.
  doi: 10.7150/ijbs.44943
– volume: 11
  year: 2021
  ident: B73
  article-title: Interactions between anti-angiogenic therapy and immunotherapy in glioblastoma.
  publication-title: Front Oncol.
  doi: 10.3389/fonc.2021.812916
– volume: 117
  start-page: 3677
  year: 2020
  ident: B81
  article-title: Activation and competition of lipoylation of H protein and its hydrolysis in a reaction cascade catalyzed by the multifunctional enzyme lipoate-protein ligase A.
  publication-title: Biotechnol Bioeng.
  doi: 10.1002/bit.27526
– volume: 58
  start-page: 6619
  year: 2015
  ident: B82
  article-title: Role of lipoylation of the immunodominant epitope of pyruvate dehydrogenase complex: toward a peptide-based diagnostic assay for primary biliary cirrhosis.
  publication-title: J Med Chem.
  doi: 10.1021/acs.jmedchem.5b00783
– start-page: 137
  year: 2022
  ident: B49
  article-title: Immune checkpoint proteins: Signaling mechanisms and molecular interactions in cancer immunotherapy.
  publication-title: Semin Cancer Biol.
  doi: 10.1016/j.semcancer.2022.03.014
– volume: 35
  start-page: 4200
  year: 2019
  ident: B61
  article-title: TISIDB: an integrated repository portal for tumor-immune system interactions.
  publication-title: Bioinformatics.
  doi: 10.1093/bioinformatics/btz210
– volume: 1
  start-page: 77
  year: 2021
  ident: B31
  article-title: Innate and adaptive immune cells in Tumor microenvironment.
  publication-title: Gulf J Oncol.
– volume: 13
  year: 2022
  ident: B43
  article-title: Correlation between immune cell infiltration and PD-L1 expression and immune-related lncRNA determination in triple-negative breast cancer.
  publication-title: Front Genet.
  doi: 10.3389/fgene.2022.878658
– volume: 10
  year: 2022
  ident: B38
  article-title: Immune cell infiltration pattern in non-small cell lung cancer PDX models is a model immanent feature and correlates with a distinct molecular and phenotypic make-up.
  publication-title: J Immunother Cancer.
  doi: 10.1136/jitc-2021-004412
– volume: 13
  year: 2021
  ident: B34
  article-title: Tumor-associated microglia and macrophages in the glioblastoma microenvironment and their implications for therapy.
  publication-title: Cancers.
  doi: 10.3390/cancers13174255
– volume: 255
  start-page: 155
  year: 2021
  ident: B35
  article-title: Immune cell analyses of the tumor microenvironment in prostate cancer highlight infiltrating regulatory T cells and macrophages as adverse prognostic factors.
  publication-title: J Pathol.
  doi: 10.1002/path.5757
– volume: 99
  year: 2019
  ident: B66
  article-title: Immunotherapy for head and neck cancer: Recent advances and future directions.
  publication-title: Oral Oncol.
  doi: 10.1016/j.oraloncology.2019.104460
– volume: 46
  start-page: D956
  year: 2018
  ident: B60
  article-title: LinkedOmics: analyzing multi-omics data within and across 32 cancer types.
  publication-title: Nucleic Acids Res.
  doi: 10.1093/nar/gkx1090
– volume: 19
  start-page: 1
  year: 2021
  ident: B58
  article-title: Chinese Glioma Genome Atlas (CGGA): a comprehensive resource with functional genomic data from chinese glioma patients.
  publication-title: Genomics Proteomics Bioinformatics.
  doi: 10.1016/j.gpb.2020.10.005
– volume: 13
  year: 2022
  ident: B75
  article-title: Pan-cancer analyses confirmed the cuproptosis-related gene FDX1 as an immunotherapy predictor and prognostic biomarker.
  publication-title: Front Genet.
  doi: 10.3389/fgene.2022.923737
– volume: 5
  year: 2022
  ident: B51
  article-title: Effectiveness of immune checkpoint inhibition vs chemotherapy in combination with radiation therapy among patients with non-small cell lung cancer and brain metastasis undergoing neurosurgical resection.
  publication-title: JAMA Netw Open.
  doi: 10.1001/jamanetworkopen.2022.9553
– volume: 56
  start-page: 149
  year: 2002
  ident: B14
  article-title: Proteases and the biology of glioma invasion.
  publication-title: J Neurooncol.
  doi: 10.1023/A:1014566604005
– volume: 1092
  start-page: 69
  year: 2018
  ident: B24
  article-title: Microenvironment influences cancer cell mechanics from tumor growth to metastasis.
  publication-title: Adv Exp Med Biol.
  doi: 10.1007/978-3-319-95294-9_5
– volume: 8
  year: 2021
  ident: B47
  article-title: Characterization of the immune cell infiltration landscape of thyroid cancer for improved immunotherapy.
  publication-title: Front Mol Biosci.
  doi: 10.3389/fmolb.2021.714053
– volume: 9
  year: 2021
  ident: B46
  article-title: Immune cell infiltration landscape of ovarian cancer to identify prognosis and immunotherapy-related genes to aid immunotherapy.
  publication-title: Front Cell Dev Biol.
  doi: 10.3389/fcell.2021.749157
– reference: 37492249 - Front Med (Lausanne). 2023 Jul 10;10:1244638
SSID ssj0001325413
Score 2.3205335
Snippet Recent studies have found that the protein encoded by the FDX1 gene is involved in mediating Cuproptosis as a regulator of protein lipoylation and related to...
Recent studies have found that the protein encoded by the gene is involved in mediating Cuproptosis as a regulator of protein lipoylation and related to immune...
Recent studies have found that the protein encoded by the FDX1 gene is involved in mediating Cuproptosis as a regulator of protein lipoylation and related to...
SourceID doaj
pubmedcentral
proquest
pubmed
crossref
SourceType Open Website
Open Access Repository
Aggregation Database
Index Database
Enrichment Source
StartPage 939776
SubjectTerms Cuproptosis
glioma
immune infiltration
lipoylation
Medicine
prognostic biomarker
SummonAdditionalLinks – databaseName: DOAJ Directory of Open Access Journals
  dbid: DOA
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Lb9QwELZQD4gLojxDCzISFw6h8SN2fCwtqwqpnKi0N8uPMay0ylbd3f_PTJKudhEqF45x7MSaGWvm84w_M_YRrIlNErlWka4w64Sqnda6LlByzg4j3ExA8fq7ubrR3-btfO-qL6oJG-mBR8GdBWsMmJKaTgcts4gJnC2xUUqBjTCQbaMb2wNTw-6KQuAj1JiXRBTmUE1AxKBSfnYU85gDPzTQ9f8txvyzVHLP98yesadT0MjPx8kes0fQP2ePr6e0-AsGF1v85u1mtV6sOa5KjlYBfHY5FxwbAqcirH5FjMycjttTRc4dD33mYVIOZE4bsnxBp0WAo9UtlhOfLj7wn0sa9ZLdzL7-uLiqp_sT6qSN3NRtMarElCWUhMgOl5rMxRbKvGFcjS4rhSaZUkJQ1mVTXHSADjtC0EFIk9QrdtSvenjDuHYliq4Eygjr2IrQKfyUsU1UndYOKnZ2L02fJnJxuuNi6RFkkPw9yd-T_P0o_4p92o24HYk1Huj7hRS060eU2EMDGoqfDMX_y1Aq9uFevR6XEOVFQg-r7dpL27YEu4St2OtR3btfKYNI3VpXMXtgCAdzOXzTL34NNN2I1DCWNm__x-RP2BOSBx2ClO6UHW3utvAOo6FNfD8Y_m9-SgrT
  priority: 102
  providerName: Directory of Open Access Journals
Title Cuproptosis key gene FDX1 is a prognostic biomarker and associated with immune infiltration in glioma
URI https://www.ncbi.nlm.nih.gov/pubmed/36523779
https://www.proquest.com/docview/2755576817
https://pubmed.ncbi.nlm.nih.gov/PMC9745336
https://doaj.org/article/a766e6fc084a42d1bce97fb0333e7be6
Volume 9
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
journalDatabaseRights – providerCode: PRVAFT
  databaseName: Open Access Digital Library
  customDbUrl:
  eissn: 2296-858X
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0001325413
  issn: 2296-858X
  databaseCode: KQ8
  dateStart: 20140101
  isFulltext: true
  titleUrlDefault: http://grweb.coalliance.org/oadl/oadl.html
  providerName: Colorado Alliance of Research Libraries
– providerCode: PRVAON
  databaseName: DOAJ Directory of Open Access Journals
  customDbUrl:
  eissn: 2296-858X
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0001325413
  issn: 2296-858X
  databaseCode: DOA
  dateStart: 20140101
  isFulltext: true
  titleUrlDefault: https://www.doaj.org/
  providerName: Directory of Open Access Journals
– providerCode: PRVBFR
  databaseName: Free Medical Journals
  customDbUrl:
  eissn: 2296-858X
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0001325413
  issn: 2296-858X
  databaseCode: DIK
  dateStart: 20140101
  isFulltext: true
  titleUrlDefault: http://www.freemedicaljournals.com
  providerName: Flying Publisher
– providerCode: PRVHPJ
  databaseName: ROAD: Directory of Open Access Scholarly Resources
  customDbUrl:
  eissn: 2296-858X
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0001325413
  issn: 2296-858X
  databaseCode: M~E
  dateStart: 20140101
  isFulltext: true
  titleUrlDefault: https://road.issn.org
  providerName: ISSN International Centre
– providerCode: PRVAQN
  databaseName: PubMed Central Free
  customDbUrl:
  eissn: 2296-858X
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0001325413
  issn: 2296-858X
  databaseCode: RPM
  dateStart: 20140101
  isFulltext: true
  titleUrlDefault: https://www.ncbi.nlm.nih.gov/pmc/
  providerName: National Library of Medicine
– providerCode: PRVFZP
  databaseName: Scholars Portal Journals: Open Access
  customDbUrl:
  eissn: 2296-858X
  dateEnd: 20250131
  omitProxy: true
  ssIdentifier: ssj0001325413
  issn: 2296-858X
  databaseCode: M48
  dateStart: 20141201
  isFulltext: true
  titleUrlDefault: http://journals.scholarsportal.info
  providerName: Scholars Portal
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9QwELagSIgLory6hVZG4sIhJbEdOz4gRAurCmk5sdLeIj_GZaVVUvYhwb_vTJIuLFr1wDGO7UTz0Mzn8cww9haM9nkoYiY9tTCrCplZpVSWIMUYLXq4kYDi5Ju-nKqvs3L2Jz16IOBqL7SjflLT5eLs18_fH1HhPxDiRHuLHACq-SnEmSV3Rt9nD9AuCZLxyeDsdycuEsFQIftY5d6FO7apK-G_z-_89_rkX_Zo_IQ9HhxJ_qnn_CG7B81T9nAyhMqfMbjY4J7X63Y1X3HUVI6SAnz8eVZwHHCcLmY1LVVp5pSCT7d0ltw1kbuBYRA5HdLyOWWQAEfazBdDjV184FcLWvWcTcdfvl9cZkNPhSwoLdZZmbRMPkQBKSDaQ_UTMZlE0Tj0tdGMBZcHnZJz0tiok_UW0Ih7cMoVQgf5gh00bQNHjCubfFElR1Fi5cvCVRK30ib3slLKwoi9v6VmHYaC49T3YlEj8CD610T_muhf9_QfsXfbFdd9sY075p4Tg7bzqEx2N9Aur-pB62pntAadQl4pp0QsfABrks-llGA84CZvbtlbo1pRrMQ10G5WtTBlSVCsMCP2smf39lNSI3o3xo6Y2RGEnX_ZfdPMf3SluxG9oX-tj_975Sv2iIhA2ZDCvmYH6-UGTtAtWvvT7jjhtJP5G5GTEYM
linkProvider Scholars Portal
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Cuproptosis+key+gene+FDX1+is+a+prognostic+biomarker+and+associated+with+immune+infiltration+in+glioma&rft.jtitle=Frontiers+in+medicine&rft.au=Lu%2C+Hanwen&rft.au=Zhou%2C+Liwei&rft.au=Zhang%2C+Bingchang&rft.au=Xie%2C+Yuanyuan&rft.date=2022-11-29&rft.pub=Frontiers+Media+S.A&rft.eissn=2296-858X&rft.volume=9&rft_id=info:doi/10.3389%2Ffmed.2022.939776&rft.externalDocID=PMC9745336
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2296-858X&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2296-858X&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2296-858X&client=summon